萬泰生物(603392.SH):將獲得基於CHOZN®ZFN-修飾細胞系的擴增純化篩選和生產技術
格隆匯 3 月 26日丨萬泰生物(603392.SH)公佈,控股股東養生堂基於其取得的CHOZN®ZFN-修飾細胞系(宿主細胞)及研發許可和商業許可,運用自身積累的Know-how技術,從事在CHOZN®ZFN-修飾細胞株的轉染、擴增,細胞株的篩選、鑑定、生產細胞庫的構建,細胞培養和純化,以及相關生產工藝的開發和驗證。
考慮到養生堂與公司之間就相互各自的產品研發和生產經營做出的避免同業競爭安排,養生堂擬與子公司萬泰滄海經協商後達成《技術轉讓合同》,就養生堂擁有的基於上述研發內容所獲得的所有細胞庫和技術文件轉讓給子公司萬泰滄海相關事宜進行約定。公司向養生堂支付相應轉讓費4261萬元(含税)。
擬籤訂的《技術轉讓合同》是避免控股股東養生堂有限公司(“養生堂”)與公司形成同業競爭或潛在同業競爭的有效措施。通過此次交易,公司將獲得基於CHOZN®ZFN-修飾細胞系的擴增純化篩選和生產技術,有助於縮短公司疫苗類產品的開發周期,加速新產品的開發上市,提升公司整體競爭實力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.